Press Coverage

Safety Watchdog Questions FDA's Approval of Parkinson's Psychosis Drug

Article describes findings from an ISMP QuarterWatch report that reviewed documents from the FDA's evaluation of pimavanserin (Nuplazid), a drug approved to treat Parkinson's disease patients with psychosis, and found a number of questions about the drug's safety and efficacy have been left unanswered. The report calls for stronger warnings on the drug label and a re-evaluation of whether Nuplazid has benefits that outweigh its still poorly defined risks.

For the full text, visit CNN online.

More News

An international medication safety call to action is aimed at preventing fatalities due to medication errors with concentrated potassium injection, inadvertent intraspinal injection of vincristine, and accidental daily instead of weekly dosing of methotrexate in patients with psoriasis or rheumatoid arthritis.